International Journal of Molecular Veterinary Research, 2024, Vol.14, No.6, 254-260 http://animalscipublisher.com/index.php/ijmvr 259 formulations, exploring novel delivery systems, and conducting large-scale field trials to validate efficacy and safety across diverse goat populations. Collaborative efforts between researchers, governments, and the livestock industry are essential to ensure the successful integration of these vaccines into existing disease control programs. The progress in vaccine development for major goat diseases is a testament to the potential of innovative approaches in veterinary medicine. The integration of immunoinformatics, gene knockout technology, and adenoviral vectors has opened new avenues for creating effective and safe vaccines. As research continues to evolve, it is crucial to maintain a focus on developing vaccines that not only protect against disease but also enhance overall animal welfare and productivity. The ultimate goal is to achieve sustainable disease control, which will contribute to improved livelihoods for farmers and the stability of the livestock industry globally. Continued investment in research and development, along with supportive policies, will be key to realizing the full potential of these vaccines in combating goat diseases. Acknowledgments Thanks to Dr. Huang for his insightful comments and suggestions from the initial proposal, data collection, to the final draft. Conflict of Interest Disclosure The author affirms that this research was conducted without any commercial or financial relationships that could be construed as a potential conflict of interest. References Adamczyk-Popławska M., Markowicz S., and Jagusztyn-Krynicka E., 2011, Proteomics for development of vaccine, Journal of proteomics, 74(12): 2596-2616. https://doi.org/10.1016/j.jprot.2011.01.019 Bezos J., Casal C., Álvarez J., Roy Á., Romero B., Rodríguez-Bertos A., Bárcena C., Díez A., Juste R., Gortázar C., Puentes E., Aguiló N., Martín C., De Juan L., and Domínguez L., 2017, Evaluation of the Mycobacterium tuberculosis SO2 vaccine using a natural tuberculosis infection model in goats, Veterinary Journal, 223: 60-67. https://doi.org/10.1016/j.tvjl.2017.04.006 Boshra H., Blyth G., Truong T., Kroeker A., Kara P., Mather A., Wallace D., and Babiuk S., 2024, The development of a multivalent capripoxvirus-vectored vaccine candidate to protect against sheeppox, goatpox, peste des petits ruminants, and rift valley fever, Vaccines, 12(7): 805. https://doi.org/10.3390/vaccines12070805 Boshra H., Truong T., Nfon C., Bowden T., Gerdts V., Tikoo S., Babiuk L., Kara P., Mather A., Wallace D., and Babiuk S., 2015, A lumpy skin disease virus deficient of an IL-10 gene homologue provides protective immunity against virulent capripoxvirus challenge in sheep and goats, Antiviral Research, 123: 39-49. https://doi.org/10.1016/j.antiviral.2015.08.016 Byadovskaya O., Shalina K., Prutnikov P., Shumilova I., Tenitilov N., Konstantinov A., Moroz N., Chvala I., and Sprygin A., 2024, The live attenuated vaccine strain “ARRIAH” completely protects goats from a virulent lineage IV field strain of peste des petits ruminants virus, Vaccines, 12(2): 110. https://doi.org/10.3390/vaccines12020110 De Pinho R., De Oliveira Silva M., Bezerra F., and Borsuk S., 2021, Vaccines for caseous lymphadenitis: up-to-date and forward-looking strategies, Applied Microbiology and Biotechnology, 105: 2287-2296. https://doi.org/10.1007/s00253-021-11191-4 De Val B., Vidal E., Villarreal-Ramos B., Gilbert S., Andaluz A., Moll X., Martin M., Nofrarías M., McShane H., Vordermeier M., Domingo M., and Wilkinson K., 2013, A multi-antigenic adenoviral-vectored vaccine improves BCG-induced protection of goats against pulmonary tuberculosis infection and prevents disease progression, PLoS One, 8(11): e81317. https://doi.org/10.1371/journal.pone.0081317 Donnarumma D., Faleri A., Costantino P., Rappuoli R., and Norais N., 2016, The role of structural proteomics in vaccine development: recent advances and future prospects, Expert Review of Proteomics, 13: 55-68. https://doi.org/10.1586/14789450.2016.1121113 Enchéry F., Hamers C., Kwiatek O., Gaillardet D., Montange C., Brunel H., Goutebroze S., Philippe-Reversat C., Libeau G., Hudelet P., and Bataille A., 2019, Development of a PPRV challenge model in goats and its use to assess the efficacy of a PPR vaccine, Vaccine, 37(12): 1667-1673. https://doi.org/10.1016/j.vaccine.2019.01.057 Hanafy M., Hansen C., Phanse Y., Wu C., Nelson K., Aschenbroich S., and Talaat A., 2023, Characterization of early immune responses elicited by live and inactivated vaccines against Johne's disease in goats, Frontiers in Veterinary Science, 9: 1046704. https://doi.org/10.3389/fvets.2022.1046704 Herbert R., Baron J., Batten C., Baron M., and Taylor G., 2014, Recombinant adenovirus expressing the haemagglutinin of peste des petits ruminants virus (PPRV) protects goats against challenge with pathogenic virus; a DIVA vaccine for PPR, Veterinary Research, 45: 24-24. https://doi.org/10.1186/1297-9716-45-24
RkJQdWJsaXNoZXIy MjQ4ODYzNA==